CALC (CalciMedica) Research & Development: $14.50 Mil (TTM As of Mar. 2026)


CALC CalciMedica Inc CALC
23 GF Score
Price $0.60
! 2 Warning Signs
View Full Analysis

What is CalciMedica Research & Development?

CalciMedica CALC -25.19% 23 Research & Development is $14.50 Mil as of Mar. 2026. GuruFocus rates CALC with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. CalciMedica's Research & Development for the three months ended in Mar. 2026 was $3.49 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $14.50 Mil.

CalciMedica  (NAS:CALC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CalciMedica Research & Development Related Terms

CalciMedica Research & Development Historical Data

* Premium members only.

The historical data trend for CalciMedica's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CalciMedica Research & Development Chart

CalciMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 18.90 8.35 15.86 14.48 15.23

CalciMedica Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.22 4.05 3.85 3.11 3.49
CALC
23GF Score
CalciMedica Inc CALC
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CalciMedica Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $14.50 Mil mean?
CalciMedica (CALC) has a Research & Development of $14.50 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on CalciMedica and its competitors.
Is CalciMedica's Research & Development too high?
CalciMedica's current Research & Development is $14.50 Mil. Overall, CalciMedica has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does CalciMedica's Research & Development compare to TOVX and PHIO?
CalciMedica's Research & Development of $14.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on CalciMedica and its competitors. CalciMedica's current Research & Development is $14.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CalciMedica stock overvalued right now?
CalciMedica (CALC) has a current Research & Development of $14.50 Mil. The current Research & Development is $14.50 Mil. CalciMedica's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For CalciMedica (CALC), the current Research & Development is $14.50 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CalciMedica Business Description

Address 505 Coast Boulevard South, Suite 307, La Jolla, CA, USA, 92037
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
23GF Score

Get the complete analysis for CALC

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.60
Price